A 52-year-old woman presents with yellow, well-demarcated plaques on her eyelids that she has noticed over the past 2 years. On examination, the lesions are soft, painless, and distributed symmetrically on the medial aspect of both upper eyelids, as shown by the marking **C** in the diagram. She is otherwise asymptomatic. Which of the following is the most appropriate next step in the management of this patient?

Explanation

## Why option 1 is correct The symmetric bilateral distribution of xanthelasma palpebrarum (marked **C**) is the hallmark presentation of this condition. According to Khurana and supported by large meta-analyses (Christoffersen 2011 Copenhagen Heart Study), approximately 50% of patients with xanthelasma have dyslipidemia (elevated LDL, low HDL, familial hypercholesterolemia, or cholestasis), but critically, 50% are normolipemic. Therefore, every patient presenting with xanthelasma must undergo fasting lipid profile and liver function tests to identify underlying lipid disorders and cholestasis, regardless of apparent lipid status. Additionally, xanthelasma is an independent marker of increased cardiovascular risk (MI, ischemic heart disease, atherosclerosis) even after adjusting for lipid levels, making systemic evaluation essential. ## Why each distractor is wrong - **Option 2**: While xanthelasma is benign histologically (lipid-laden foam cells without granulomatous inflammation), it is NOT cosmetically insignificant to most patients and, more importantly, represents a cardiovascular risk marker that warrants metabolic and hepatic evaluation. Reassurance without investigation misses the opportunity to identify dyslipidemia or liver disease. - **Option 3**: Surgical excision is a cosmetic option for thick lesions (with ~30% recurrence), but it is not the first management step. Primary management is lipid control and cardiovascular risk reduction. Excision does not address the underlying metabolic abnormality and should only be considered after lipid assessment and medical optimization. - **Option 4**: Empirical statin therapy without baseline lipid assessment is inappropriate because 50% of xanthelasma patients are normolipemic. Starting statins without confirming dyslipidemia exposes the patient to unnecessary medication and side effects. Baseline lipid and liver function tests must guide therapy. **High-Yield:** Xanthelasma = most common cutaneous xanthoma; symmetric bilateral periorbital distribution warrants fasting lipid profile + LFTs in ALL patients (50% dyslipidemic, 50% normolipemic), and represents independent cardiovascular risk even if lipids are normal. [cite: AK Khurana Ophthalmology 7e; Christoffersen et al. Copenhagen Heart Study]